TICKERNOMICS Sign up
Last Update: 2024-12-27 15:29:13
Carisma Therapeutics Inc. ( CARM )
0.44USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-85.60%
CARM
SPY
32.66%
-94.93%
CARM
SPY
108.59%
-95.77%
CARM
SPY
302.52%
-99.65%
CARM
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
1.74
-23.00
0.30
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.03
0.09
-0.16
-200.31
0.00
0.45
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-388.30
100.00
-266.12
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
9.9872
-128.12
-91.13
1.54
Other Earnings and Cash Flow Stats:
Carisma Therapeutics Inc. ( CARM ) Net Income TTM ($MM) is -63.80
Carisma Therapeutics Inc. ( CARM ) Operating Income TTM ($MM) is -66.77
Carisma Therapeutics Inc. ( CARM ) Owners' Earnings Annual ($MM) is 0.00
Carisma Therapeutics Inc. ( CARM ) Current Price to Owners' Earnings ratio is 0.00
Carisma Therapeutics Inc. ( CARM ) EBITDA TTM ($MM) is -62.11
Carisma Therapeutics Inc. ( CARM ) EBITDA Margin is -266.12%
Capital Allocation:
Carisma Therapeutics Inc. ( CARM ) has paid 0.00 dividends per share and bought back 36.127055 million shares in the past 12 months
Carisma Therapeutics Inc. ( CARM ) has increased its debt by 0.4 million USD in the last 12 months
Capital Structure:
Carisma Therapeutics Inc. ( CARM ) Interest-bearing Debt ($MM) as of last quarter is 2
Carisma Therapeutics Inc. ( CARM ) Annual Working Capital Investments ($MM) are 1
Carisma Therapeutics Inc. ( CARM ) Book Value ($MM) as of last quarter is -12
Carisma Therapeutics Inc. ( CARM ) Debt/Capital as of last quarter is -20%
Other Balance Sheet Stats:
Carisma Therapeutics Inc. ( CARM ) has 26 million in cash on hand as of last quarter
Carisma Therapeutics Inc. ( CARM ) has 10 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Carisma Therapeutics Inc. ( CARM ) has 4 common shares outstanding as of last quarter
Carisma Therapeutics Inc. ( CARM ) has 0 million USD of preferred stock value
Academic Scores:
Carisma Therapeutics Inc. ( CARM ) Altman Z-Score is -12.94 as of last quarter
Carisma Therapeutics Inc. ( CARM ) Piotroski Score is 5.00 as of last quarter
Corporate Governance:
Carisma Therapeutics Inc. ( CARM ) largest shareholder is owning shares at 0.00 ($MM) value
(an insider) shares of Carisma Therapeutics Inc. ( CARM ) for the amount of $ on
28.54% of Carisma Therapeutics Inc. ( CARM ) is held by insiders, and 33.65% is held by institutions
Carisma Therapeutics Inc. ( CARM ) went public on 2014-02-06
Other Carisma Therapeutics Inc. ( CARM ) financial metrics:
FCF:-84.05
Unlevered Free Cash Flow:0.00
EPS:-12.22
Operating Margin:-388.30
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:456.66
Beta:1.54
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Carisma Therapeutics Inc. ( CARM ) :
Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics, Inc. has a strategic collaboration agreement with Moderna Inc. Carisma Therapeutics, Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was incorporated in 2016 and is based in Philadelphia, Pennsylvania.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.